title: Anti-cholesterol antibodies (ACHA) in patients with different atherosclerotic vascular diseases and healthy individuals. Characterization of human ACHA.
abstract: In animal experiments the protective role of anti-cholesterol antibodies (ACHA) in the development of atherosclerosis has been demonstrated. Despite the fact that ACHA are present in the serum of healthy humans, no data on the occurrence of these antibodies in human diseases are available. We determined serum concentrations of IgG type ACHA by an enzyme immunosorbent assay in 600 patients with atherosclerotic vascular diseases (86 patients with peripheral occlusive atherosclerosis, 146 patients with cerebrovascular diseases, 341 patients with severe coronary heart disease (CHD) who received aorto-coronary by-pass, 27 patients with myocardial infarction who did not undergo by-pass operation), in 57 patient controls (complaints of CHD, without coronarographic alterations) and in 218 healthy individuals. ACHA were present in the sera of all persons tested. No serum cofactor is needed for the binding of human ACHA to solid phase cholesterol, binding can be inhibited dose-dependently by LDL and even more strongly with LDL/VLDL preparations purified from human serum. ACHA levels were found to be considerably lower in patients with peripheral occlusive atherosclerosis and cerebrovascular diseases compared with the levels in healthy individuals. By contrast, the ACHA levels of patients with CHD were considerably higher. No differences in the IgG subclass distribution and binding efficiency of ACHA in the sera of CHD patients and controls were found. Thus, our present findings indicate that both low and high ACHA production may be associated with different atherosclerotic vascular diseases.
authors.affiliation: Third Department of Medicine, Faculty of Medicine, Semmelweis University, Kútvölgyi út 4, Budapest 1125, Hungary. horann@kut.sote.hu
authors.forename: A
authors.initials: A
authors.lastname: Horváth
authors.forename: G
authors.initials: G
authors.lastname: Füst
authors.forename: I
authors.initials: I
authors.lastname: Horváth
authors.forename: G
authors.initials: G
authors.lastname: Vallus
authors.forename: J
authors.initials: J
authors.lastname: Duba
authors.forename: P
authors.initials: P
authors.lastname: Harcos
authors.forename: Z
authors.initials: Z
authors.lastname: Prohászka
authors.forename: E
authors.initials: E
authors.lastname: Rajnavölgyi
authors.forename: L
authors.initials: L
authors.lastname: Jánoskuti
authors.forename: M
authors.initials: M
authors.lastname: Kovács
authors.forename: A
authors.initials: A
authors.lastname: Császár
authors.forename: L
authors.initials: L
authors.lastname: Romics
authors.forename: I
authors.initials: I
authors.lastname: Karádi
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis* / Q000276:immunology*; D000918:Antibody Specificity; D001161:Arteriosclerosis / Q000276:immunology*; D001782:Blood Donors; D002561:Cerebrovascular Disorders / Q000276:immunology; D002784:Cholesterol / Q000276:immunology*; D003327:Coronary Disease / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012016:Reference Values
chemical_list: D000906:Antibodies; D007074:Immunoglobulin G; D002784:Cholesterol